Pharmacokinetic and pharmacodynamic evaluation of site-specific pegylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers

Su Young Chae, Goo Young Chun, Seulki Lee, Cheng Hao Jin, Eun Seong Lee, Kang Choon Lee, Yu Seok Youn

Research output: Contribution to journalArticlepeer-review

Abstract

The rapid elimination of glucagon-like peptide-1 (GLP-1) is the main impediment to its anti-diabetic utility. Here, we tried to improve its poor pharmacokinetic/pharmacodynamic profiles using PEGylation. The site-specific (Lys34) PEGylated GLP-ls were synthesized with PEGs of 2, 5, and 10 kDa, respectively. Oral glucose tolerance tests using d6/d6 mice showed that these three PEGylated GLP-ls (5 nmol/kg) specifically stabilized plasma glucose levels when intraperitoneally (i.p.) administered at 30, 30-120, or 120-360 min preoral glucose treatment, respectively (total hypoglycemic degree: 60.5 ±5.0%; ̃67.2±2.3%; and ∼59.4±4.3%, respectively). Particularly, Lys34-PEGioK-GLP-l showed an stable hypoglycemic efficacy when administered up to 360 min preglucose. The different anti-diabetic effects of PEGylated GLP-ls were attributed to their augmented pharmacokinetics and metabolic resistance. These analogs had higher metabolic stabilities in rat plasma, liver and kidney homogenates, and extended pharmacokinetic profiles with the greater circulating half-lives (26.6,64.5, and 105.5 min for Lys 34-PEG2,5,10,K-GLP-ls, respectively, vs. 8.5 min for GLP-1, at elimination phases after i.p. injections) in ICR mice. Our findings suggest that GLP-1 substituted with a PEG of an appropriate Mw at Lys 34 could be used as a promising type 2 anti-diabetic agent to timely control postprandial glucose levels.

Original languageEnglish (US)
Pages (from-to)1556-1567
Number of pages12
JournalJournal of Pharmaceutical Sciences
Volume98
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Keywords

  • Glucagon-like peptide-1
  • Hypoglycemic efficacy
  • Pegylation
  • Pharmacokinetics
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Pharmacokinetic and pharmacodynamic evaluation of site-specific pegylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers'. Together they form a unique fingerprint.

Cite this